This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Barta SK , Zain J , MacFarlane AW4th , Smith SM , Ruan J , Fung HC , Tan CR , Yang Y , Alpaugh RK , Dulaimi E , Ross EA , Campbell KS , Khan N , Siddharta R , Fowler NH , Fisher RI , Oki Y
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6) :356-364 e3
PMID: 31029646 URL: https://www.ncbi.nlm.nih.gov/pubmed/31029646
AbstractBACKGROUND: Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are frequently expressed in T-cell lymphomas. This provides a rationale for exploration of immune checkpoint inhibitors in the management of T-cell lymphomas. PATIENTS AND METHODS: In this phase II single-arm multicenter trial, patients with relapsed or refractory systemic T-cell lymphoma were treated with 200 mg pembrolizumab intravenously every 21 days. The primary endpoint was progression-free survival (PFS). The secondary endpoints were response rate, overall survival, response duration, and safety. We assessed PD-L1, p-AKT expression, and peripheral blood immune cells as potential predictive biomarkers. RESULTS: Of 18 enrolled patients, 13 were evaluable for the primary endpoint. The trial was halted early after a preplanned interim futility analysis. The overall response rate was 33% (95% confidence interval [CI], 9%-55%); 4 patients achieved a complete response (27%; 95% CI, 5%-49%). The median PFS was 3.2 months (95% CI, 1.2-3.7 months), and the median overall survival was 10.6 months (95% CI, 3.2-100 months). The median duration of response was 2.9 months (95% CI, 0-10.1 months). Two of the 4 complete responders remain in remission > 15 months. Rash was the most common adverse event (17%; n = 3). The most common >/= grade 3 treatment-emergent adverse events were rash and pneumonitis (11%; n = 2 each). Neither PD-L1 nor p-AKT expression were associated with outcomes. However, a higher relative frequency of CD4(+) T lymphocytes pre-treatment was associated with improved PFS (hazard ratio, 0.15; 95% CI, 0.03-0.74). CONCLUSION: Pembrolizumab demonstrated modest single-agent activity in relapsed or refractory T-cell lymphoma.
Notes2152-2669 Barta, Stefan K Zain, Jasmine MacFarlane, Alexander W 4th Smith, Sonali M Ruan, Jia Fung, Henry C Tan, Carlyn R Yang, Yibin Alpaugh, R Katherine Dulaimi, Essel Ross, Eric A Campbell, Kerry S Khan, Nadia Siddharta, Rawat Fowler, Nathan H Fisher, Richard I Oki, Yasuhiro Journal Article United States Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3. doi: 10.1016/j.clml.2019.03.022. Epub 2019 Apr 3.